Get the Stockscreener App
2.72
0.37%
0.01
After Hours:
2.67
-0.05
-1.84%
Fortress Biotech Inc stock is traded at $2.72, with a volume of 168.12K.
It is up +0.37% in the last 24 hours and up +0.00% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See More
Previous Close:
$2.71
Open:
$2.68
24h Volume:
168.12K
Relative Volume:
0.29
Market Cap:
$90.71M
Revenue:
$66.16M
Net Income/Loss:
$128.94M
P/E Ratio:
0.8547
EPS:
3.1823
Net Cash Flow:
$152.08M
1W Performance:
-1.81%
1M Performance:
+0.00%
6M Performance:
-12.26%
1Y Performance:
-4.23%
1-Day Range:
$2.675
$2.74
1-Week Range:
$2.63
$2.795
52-Week Range:
$2.18
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.72 | 92.38M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech (FBIO) Rises to $2.73 as Buyers Defend Key Support ZoneWide Range Bar - dars.gov.et
Integrated Core Strategies (US) LLC Discloses 5.3% Stake in Fortress Biotech (NASDAQ: FBIO) via 13G Filing - Kalkine Media
Passive stake disclosed in Fortress Biotech (NASDAQ: FBIO) by Millennium group - Stock Titan
(FBIOP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
FBIO Should I Buy - Intellectia AI
Fortress Biotech Inc. (FBIO) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
FBIO | Fortress Biotech, Inc. FinancialsRevenue Breakdown - Quiver Quantitative
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript - AOL.ca
ETFs Investing in Fortress Biotech, Inc. Stocks - TradingView
Fortress Biotech (FBIO) Slips 1.68% to $2.93 as Small-Cap Biotech Faces PressureBollinger Squeeze - vinanet.vn
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Fortress Biotech (FBIO) Pulls Back 3% as Shares Approach Key $2.75 SupportFear Greed Index - vinanet.vn
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Fortress Biotech earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Fortress Biotech: Q2 Earnings Snapshot - marketscreener.com
Fortress Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary - TradingView
Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash - Stock Titan
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire
Fortress Biotech Q2 Earnings Call Highlights - MarketBeat
FBIO Looks 125.0% Overvalued on GF Value™ Ahead of Q2 Earnings - GuruFocus
Fortress Biotech (FBIO) Q2 2026 Earnings Call - finance.biggo.com
Fortress Biotech Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
The Technical Signals Behind (FBIOP) That Institutions Follow - Stock Traders Daily
FBIO Q1 2026 Earnings: Significant EPS Miss Triggers Modest Stock DeclineDiluted EPS Report - vinanet.vn
Law firm investigates Fortress Biotech for poss... - Pluang
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after market close on August 12. - 富途牛牛
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO) - PR Newswire
Fortress Biotech (FBIO) to Release Earnings on Thursday - MarketBeat
Fortress Biotech Preferred (FBIOP) Holds Steady Near $18.91: Testing Key Support and ResistanceExhaustion Gap - dars.gov.et
Best Cheap Stocks Under $10 with High Return Potential (August 2026) - Investing.com
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech Just Netted $159 MillionIts Preferred Shares Could Be The Real Winner - Seeking Alpha
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing - marketscreener.com
Fortress Biotech Preferred Stock (FBIOP) Edges Lower Amid Quiet Trading – Key Support and Resistance Levels in FocusSign of Weakness - dars.gov.et
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Balance Sheet - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing - The Manila Times
FBIO|Fortress Biotech Inc|Price:3.340|Chg%:-0.090 - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Journey Medical Corp (DERM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Income Statement - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy - Seeking Alpha
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):